Table 7.
Summary of post-discontinuation treatment
| Any post-discontinuation therapy after mahalanobis distance matching | MONARCH 1 N = 108 |
Real-world cohort N = 108 |
|---|---|---|
| Patients with any post-discontinuation therapy, n (%) | 77 (71.3) | 71 (65.7) |
| Chemotherapya, n (%) | 65 (60.2) | 61 (56.5) |
| Capecitabine | 26 (24.1) | 14 (13.0) |
| Eribulin | 18 (16.7) | 18 (16.7) |
| Doxorubicin | 16 (14.8) | 3 (2.8) |
| Paclitaxel | 15 (13.9) | 16 (14.8) |
| Vinorelbine | 13 (12.0 | 11 (10.2) |
| Gemcitabine | 3 (2.8) | 17 (15.7) |
| Doxorubicin pegylated liposomal | 0 | 19 (17.6) |
| Otherb | 18 (16.7) | 50 (46.3) |
| Endocrine therapyc, n (%) | 13 (12.0) | 50d (46.3) |
| Fulvestrant | 6 (5.6) | 17 (15.7) |
| Exemestane | 3 (2.8) | 15 (13.9) |
| Letrozole | 3 (2.8) | 26 (24.1) |
| Othere | 4 (3.7) | 9 (8.3) |
| Targeted therapy, n (%) | 8 (7.4) | 41 (38.0) |
| Everolimus | 5 (4.6) | 10 (9.3) |
| Palbociclib | 0 | 32 (29.6) |
| Otherf | 3 (2.8) | 5 (4.6) |
| Other, n (%) | 8 (7.4) | 6 (5.6) |
| Investigational drug | 6 (5.6) | 4 (3.7) |
| Otherg | 2 (1.9) | 2 (1.9) |
CDK Cyclin-dependent kinases, N total number of patients, n number of patients within a specific category
aAny single chemotherapy agent with > 10% in either arm is listed; all other therapies are combined into ‘other’
bOther chemotherapy agents include cyclophosphamide, fluorouracil, docetaxel, cisplatin w/fluorouracil, cyclophosphamide w/epirubicin hydrochloride/f, cyclophosphamide w/fluorouracil/methotrexate, epirubicin, lurbinectedin, methotrexate, thiotepa, carboplatin, cisplatin, etoposide, irinotecan, and ixabepilone
cAny endocrine, targeted, or other therapy with > 5% in either arm is listed; all other therapies are combined into ‘other’
d32 out of 50 patients who received endocrine therapy also received concurrent CDK4 & 6 inhibitor
eOther endocrine therapy regimens include tamoxifen, orteronel, anastrozole, and leuprolide
fOther targeted therapies include bevacizumab, cabozantinib, trastuzumab, nivolumab, and ribociclib
gOther therapies include dexrazoxane, doxycycline, and leucovorin